Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 9/20 | 0.43 |
| ▸ | PPARG | P37231 | 8/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | MPC2 | O95563 | 1/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14281402 | 0.92 | FFAR1 (0.43) | FFAR1PPARGALDH1A1NPSR1MAPT | |
| SCHEMBL9832774 | 0.86 | ALDH1A1 (0.45) | FFAR1PPARGALDH1A1NPSR1MAPT | |
| SCHEMBL9831543 | 0.85 | MAPT (0.58) | FFAR1PPARGALDH1A1NPSR1MAPT | |
| SCHEMBL9565667 | 0.85 | MAPT (0.53) | FFAR1PPARGALDH1A1NPSR1MAPT | |
| SCHEMBL9829846 | 0.85 | PPARG (0.49) | FFAR1PPARGALDH1A1NPSR1PPARA | |
| SCHEMBL9832866 | 0.85 | FFAR1 (0.57) | FFAR1PPARGPPARAMPC2CYP2C8 | |
| SCHEMBL290976 | 0.84 | UTRN (0.48) | FFAR1PPARGALDH1A1NPSR1MAPT | |
| SCHEMBL29702319 | 0.84 | UTRN (0.48) | FFAR1PPARGALDH1A1NPSR1MAPT | |
| SCHEMBL9833714 | 0.83 | ALDH1A1 (0.44) | FFAR1PPARGALDH1A1NPSR1MAPT | |
| SCHEMBL9468083 | 0.83 | ALDH1A1 (0.44) | FFAR1PPARGALDH1A1NPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682125-B2 | Compositions and methods for treating cognitive deficits | CASE WESTERN RESERVE UNIVERSITY (US) | 2017-06-20 | — | — | US | claimed |
| US-20140364461-A1 | METHOD OF TREATING DERMATOLOGICAL DISORDERS | UNIV CASE WESTERN RESERVE (US) | 2014-12-11 | — | — | US | claimed |
| US-20140335105-A1 | METHODS OF GENERATING HYPER INOS EXPRESSING CELLS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-11-13 | — | — | US | claimed |
| US-20140235676-A1 | RXR AGONIST COMPOUNDS AND METHODS | UNIV CASE WESTERN RESERVE (US) | 2014-08-21 | — | — | US | claimed |
| EP-2766018-A2 | RXR AGONISTS COMPOUNDS AND METHODS | Case Western Reserve University (US) | 2014-08-20 | — | — | EP | claimed |
| US-8796282-B2 | Method of treating dermatological disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-08-05 | — | — | US | claimed |
| US-8790925-B2 | Methods of generating hyper iNOS expressing cells and uses thereof | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-07-29 | — | — | US | claimed |
| US-20140170165-A1 | METHODS OF GENERATING HYPER INOS EXPRESSING CELLS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-06-19 | — | — | US | claimed |
| WO-2013056232-A2 | RXR AGONISTS COMPOUNDS AND METHODS | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-04-18 | — | — | WO | claimed |
| EP-2451455-A2 | RXR AGONIST COMPOUNDS AND METHODS | Case Western Reserve University (US) | 2012-05-16 | — | — | EP | claimed |
| WO-2008070230-A2 | METHODS AND COMPOSITIONS FOR TREATING CENTRAL NERVOS SYSTEM TUMORS | CASE WESTERN RESERVE UNIVERSITY (US) | 2008-06-12 | — | — | WO | claimed |
| WO-2008024749-A2 | METHODS AND COMPOSITIONS FOR TREATING ISCHEMIC STROKE | CASE WESTERN RESERVE UNIVERSITY (US) | 2008-02-28 | — | — | WO | claimed |
| WO-2007127791-A2 | NEW PHARMACOLOGICAL METHOD FOR TREATMENT OF NEUROPATHIC PAIN | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2007-11-08 | — | — | WO | claimed |
| US-20070249561-A1 | Pharmacological method for treatment of neuropathic pain | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND | 2007-10-25 | — | — | US | claimed |
| WO-2006132928-A2 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION | CASE WESTERN RESERVE UNIVERSITY (US) | 2006-12-14 | — | — | WO | claimed |
| US-6579893-B1 | Related thiazolidinediones | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-06-17 | — | — | US | claimed |
| EP-0535269-A1 | Pharmaceutical compositions containing thiazolidinedione derivatives | TANABE SEIYAKU CO., LTD. (JP) | 1993-04-07 | — | — | EP | claimed |
| EP-0283035-B1 | BENZOXAZOLE DERIVATIVES AND PREPARATION THEREOF | TANABE SEIYAKU CO., LTD. (JP) | 1991-11-06 | — | — | EP | claimed |
| US-4897393-A | ANTIDIABETIC AGENTS | TANABE SEIYAKU CO., LTD. (JP) | 1990-01-30 | — | — | US | claimed |
| EP-0283035-A1 | Benzoxazole derivatives and preparation thereof | TANABE SEIYAKU CO., LTD. (JP) | 1988-09-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249561-A1 | Pharmacological method for treatment of neuropathic pain | PPARG, PPARA, CNR2 | FFAR1 167/4885PPARG 1/4885ALDH1A1 1335/4885 |
| US-20140364461-A1 | METHOD OF TREATING DERMATOLOGICAL DISORDERS | PPARA, PPARG, PPARD | FFAR1 375/4885PPARG 2/4885ALDH1A1 484/4885 |
| US-20140235676-A1 | RXR AGONIST COMPOUNDS AND METHODS | RXRA, RXRB, RXRG | FFAR1 240/4885PPARG 20/4885ALDH1A1 2954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.